Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma

Chemico-Biological Interactions

Volumn 215, Issue 1, 2014, Pages 17-24

  Mansour, Mahmoud A ^a   Aljoufi, Mohammed A ^b   Al Hosaini, Khaled ^b   Al Rikabi, Ammar C ^c   Nagi, Mahmoud N ^b  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Carfilzomib; Hepatocellular carcinoma; Proteasome inhibitor

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CARCINOGEN; CARFILZOMIB; DIETHYLNITROSAMINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; METALLOTHIONEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER CELL; LIVER CELL CARCINOMA; LIVER HOMOGENATE; LIVER NODULE; LIVER PROTECTION; LIVER SIZE; MALE; NECROSIS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION; TREATMENT OUTCOME;

CARFILZOMIB; HEPATOCELLULAR CARCINOMA; PROTEASOME INHIBITOR;

ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; ENDOSTATINS; FIBROBLAST GROWTH FACTOR 2; LIVER; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; METALLOTHIONEIN; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896919877     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.03.001     Document Type: Article

References (46)

1. D.F. Schafer, and M.F. Sorrell Hepatocellular carcinoma Lancet 353 1999 1253 1257
2. K. Kasai, H. Kuroda, and K. Suzuki Adjuvant therapy after treatment of hepatocellular carcinoma Nippon Shokakibyo Gakkai Zasshi 105 2008 787 794
3. M. Scheffner Ubiquitin, E6-Ap, and their role in p53 inactivation Pharmacol. Ther. 78 3 1998 129 139
4. Q. Dou, and B. Li Proteasome inhibitors as potential novel anticancer agent Drug Resist. Updates 2 1999 215 223
5. S.M. Bang, J.H. Lee, S.S. Yoon, S. Park, C.K. Min, C.C. Kim, C. Suh, S.K. Sohn, Y.H. Min, and J.J. Lee A Multicenter retrospective analysis of adverse events in korean patients using bortezomib for multiple myeloma Int. J. Hematol. 83 2006 309 313
6. M. Cervello, L. Giannitrapani, M. La Rosa, M. Notarbartolo, M. Labbozzetta, P. Poma, G. Montalto, and N. D'Alessandro Induction of apoptosis by the proteasome inhibitor mg132 in human hcc cells: possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation Int. J. Mol. Med. 13 2004 741 748
7. J.L. Brown N-Nitrosamines Occup. Med. 14 1999 839 848
8. B.P. Sullivan, T.J. Meyer, M.T. Stershic, and L.K. Keefer Acceleration of N-nitrosation reactions by electrophiles IARC Sci. Publ. 1991 370 374
9. B.D. Reh, and J.M. Fajen Worker exposures to nitrosamines in a rubber vehicle sealing plant Am. Ind. Hyg. Assoc. J. 57 1996 918 923
10. P. Bhosale, L. Motiwale, A.D. Ingle, R.B. Gadre, and K.V.K. Rao Protective effect of rhodotorula glutinis ncim3353 on the development of hepatic preneoplastic lesions Curr. Sci. 83 2002 303 308
11. H.C. Pitot, and A.E. Sirica The stages of initiation and promotion in hepatocarcinogenesis Biochim. Biophys. Acta 605 1980 191 215
12. M. Tatematsu, Y. Nagamine, and E. Farber Stable phenotypic expression of glutathione-S-transferase placental type and unstable phenotypic expression of γ-glutamyl transpeptidase in rat liver preneoplastic and neoplastic lesions Carcinogenesis 9 1988 215 220
13. J. Yang, Z. Wang, Y. Fang, J. Jiang, F. Zhao, H. Wong, M.K. Bennett, C.J. Molineaux, and C.J. Kirk Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats Drug Metab. Dispos. 39 2011 1873 1882
14. W.S. Ha, C.K. Kim, S.H. Song, and C.B. Kang Study on mechanism of multistep hepatotumorigenesis in rat: development of hepatotumorigenesis J. Vet. Sci. 2 2001 53 58
15. G. Ramakrishnan, H.R. Raghavendran, R. Vinodhkumar, and T. Devaki Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats Chem. Biol. Interact. 161 2006 104 114
16. D. Church, R. Midgley, and D. Kerr Biomarkers in early-stage colorectal cancer: ready for prime time? Dig. Dis. 30 2012 27 33
17. M.J. Clark, K. Robien, and J.L. Slavin Effect of prebiotics on biomarkers of colorectal cancer in humans: a systematic review Nutr. Rev. 70 2012 436 443
18. X.Y. Wu, X.E. Huang, and S.X. You et al. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer Asian Pac. J. Cancer Prev. 14 2013 2019 2022
19. M. Turriziani, M. Fantini, and M. Benvenuto et al. Carcinoembryonic antigen (cea)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials Recent Pat. Anticancer Drug Discov. 7 2012 265 296
20. L. Spelt, B. Andersson, and J. Nilsson et al. Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review Eur. J. Surg. Oncol. 38 2012 16 24
21. R. Zimmer, and P. Thomas Mutations in the carcinoembryonic antigen gene in colorectal cancer patients: implications on liver metastasis Cancer Res. 61 2001 2822 2826
22. H. Yoshiji, S. Kuriyama, and H. Fukui Angiotensin-1-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. possible role of vascular endothelial growth factor Anticancer Drugs 13 2002 221 228
23. S. Jagan, G. Ramakrishan, P. Anandakumar, S. Kamaraj, and T. Devaki Antiproliferative potential of gallic acid against diethylnitrosoamine-induced rat hepatocellular carcinoma Mol. Cell. Biochem. 319 2008 51 59
24. M. Klagsbrun, and P.A. D'Amore Vascular endothelial growth factor and its receptors Cytokine Growth Factor Rev. 7 1996 259 270
25. N.H. Chow, P.I. Hsu, X.Z. Lin, H.B. Yang, S.H. Chan, K.S. Cheng, S.M. Huang, and I.J. Su Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study Hum. Pathol. 28 1997 698 703
26. M. Korc, and R.E. Friesel The role of fibroblast growth factors in tumor growth Curr. Cancer Drug Targets 9 5 2009 639 651
27. N. Turner, and R. Grose Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 10 2 2010 116 129
28. G. Bergers, and D. Hanahan Modes of resistance to antiangiogenic therapy Nat. Rev. Cancer 8 8 2008 592 603
29. S. Tsunoda, T. Nakamura, H. Sakurai, and I. Saiki Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor a-dependent neovascularization Cancer Sci. 98 4 2007 541 548
30. R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M.P. Tosatti, and M. Presta Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis Am. J. Pathol. 162 6 2003 1913 1926
31. X. Huang, C. Yu, C. Jin, M. Kobayashi, C.A. Bowles, F. Wang, and W.L. McKeehan Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis Cancer Res. 66 2006 1481 1490
32. 1- induced changes in cell migration, proliferation and angiogensis in the chicken chorioallantoic membrane J. Cell Biol. 111 1990 731 741
33. 1 levels with tumor vascularity in hepatocellular carcinoma Cancer Lett. 89 1995 45 48
34. 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth Biochim. Biophys. Acta 1137 1992 189 196
35. M.A. Mansour, H. Al-Ismaeel, A.C. Al-Rikabi, and O.A. Al-Shabanah Comparison of angiotensin converting enzyme inhibitors and angiotensin ii type 1 receptor blockade for the prevention of premalignant changes in the liver Life Sci. 89 2011 188 194
36. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
37. A. Hoeben, B. Landuyt, M.S. Highley, H. Wildiers, A.T. Van Oosterom, and E.A. De Bruijn Vascular endothelial growth factor and angiogenesis Pharmacol. Rev. 56 2004 549 580
38. X. Li, Y. Liu, S. Lee, T. Gardner, M. Jeng, and C. Kao Prostate restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy Clin. Cancer Res. 14 2008 291 299
39. L.J. Lai, X. Xiao, and J.H. Wu Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model J. Biomed. Sci. 14 2007 313 322
40. L. Fang, Y.Y. Pu, X.C. Hu, L.J. Sun, H.M. Luo, S.K. Pan, J.Z. Gu, X.R. Cao1, and C.Q. Su Antiangiogenesis gene armed tumor-targeting adenovirus yields multiple antitumor activities in human hcc xenografts in nude mice Hepatol. Res. 40 2010 216 228
41. L. Zhang, W. Zhou, V.E. Velculescu, S.E. Kern, R.H. Hruban, S.R. Hamilton, B. Vogelstein, and K.W. Kinzler Gene expression profiles in normal and cancer cells Science 276 1997 1268 1272
42. M.G. Cherian, A. Jayasurya, and B.H. Bay Metallothioneins in human tumors and potential roles in carcinogenesis Mutat. Res. 533 2003 201 209
43. Y. Huang, A. de la Chapelle, and N.S. Pellegata Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma Int. J. Cancer 104 2003 735 744
44. T. Endo, M. Yoshikawa, M. Ebara, K. Kato, M. Sunaga, H. Fukuda, A. Hayasaka, F. Kondo, N. Sugiura, and H. Saisho Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents J. Gastroenterol. 39 2004 1196 1201
45. A. Nakayama, H. Fukuda, M. Ebara, H. Hamasaki, K. Nakajima, and H. Sakurai A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels Biol. Pharm. Bull. 25 2002 426 443
46. D. Kardum, J. Huskic, D. Fabijanic, M. Banic, M. Buljevac, and M. Kujundzic et al. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma Eur. J. Gastroenterol. Hepatol. 11 1999 1209 1213